Although some recent 2025 studies have begun to establish longitudinal associations—such as PCSK9 predicting CKD progression in diabetes—large, multicenter trials are needed to validate the prognostic utility of these biomarkers and their incremental value beyond traditional markers like eGFR and albuminuria. This evidence concerns the gene PCSK9 and chronic kidney disease.